Home

Robert Carey

CIK 1602064 · EVP, Chief Business Officer · last filed 2025-11-07

Robert Carey is an EVP, Chief Business Officer who has filed 71 SEC Form 4 insider transactions across 4 companies since 2014. The most recent filing, for XAIR, was dated Nov 7, 2025. Across all open-market trades the lifetime net is +$8.9M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $44.3K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$44.3K

Companies

4

Total Filings

71

Lifetime Open-Market Net

$8.91M

Filer Profile

Reported Address
SANGAMO THERAPEUTICS, INC.
501 CANAL BLVD.
RICHMOND, CA 94084
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
XAIR Director 13,859 $3.20 $44.3K $9.42M 36 2025-11-07
SANGAMO THERAPEUTICS, INC (SGMO) Delisted Director 99,600 $0.18 $17.7K $0 11 2025-06-16
Horizon Therapeutics Public Ltd Co (HZNP) Delisted EVP, Chief Business Officer 266,358 $116.30 $30.98M -$509.8K 17 2019-03-25
ARGOS THERAPEUTICS INC (ARGS) Delisted Director 410 — — $0 6 2017-01-20

Recent Filings

71 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2025-11-07 XAIR Mixed — $0 EDGAR
2025-11-07 XAIR Mixed — $0 EDGAR
2025-06-16 SANGAMO THERAPEUTICS, INC (SGMO) Delisted Grant (A) +25,000 $0 EDGAR
2025-03-28 XAIR Grant (A) — $0 EDGAR
2025-03-17 XAIR Buy (P) +1,000,000 $250.1K EDGAR
2024-11-26 XAIR Mixed — $0 EDGAR
2024-10-01 XAIR Mixed +1,476,626 $744.7K EDGAR
2024-08-15 XAIR Buy (P) +100,000 $39.7K EDGAR
2024-06-06 SANGAMO THERAPEUTICS, INC (SGMO) Delisted Grant (A) +25,000 $0 EDGAR
2024-03-21 XAIR Grant (A) +602,410 $1.00M EDGAR
Showing 1–10 of 71
Page 1 of 8
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.